ArticleHemaSphere2020

Identification of Fusion Gene Breakpoints is Feasible and Facilitates Accurate Sensitive Minimal Residual Disease Monitoring on Genomic Level in Patients With PML-RARA, CBFB-MYH11, and RUNX1-RUNX1T1.

Julius Lukes et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.